Vaxine Not Working - What's the Impact?

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

In europe, they had preordered over 400 million doses of this thing. There's just so many other good vaccines to fill in the gap. He'll slow things down by a little bit, but it won't be a huge blow. But time will tellso we've been saying for months and months on cenipot,. that although we've got ready good vacazines that of working well, we always need more road ahead of us.

After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.

News: CureVac COVID vaccine let-down spotlights mRNA design challenges

News Feature: How COVID unlocked the power of RNA vaccines

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.